Miltenyi Biomedicine Gmbh

This study tests a new treatment for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, which are genetically modified to recognize and attack cancer cells. The go…

This study tests a new treatment called MB-CART2019.1 for people with a type of blood cancer (diffuse large B-cell lymphoma) that has come back or not responded to treatment. Participants are not able to have a standard stem cell transplant. The study compares the new cell therap…

This study tests a new treatment called MB-CART 2019.1 for people with active multiple sclerosis (MS) that hasn't responded to other therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack harmful immune cells driving MS. The goal is to …

This study tests a new treatment using a patient's own immune cells, modified to target and destroy faulty B cells that drive autoimmune diseases like lupus, scleroderma, and myositis. Up to 24 adults with active disease will receive the therapy after a short chemotherapy course.…

This trial tests a new treatment for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack leukemia cells. …

This study tests a new treatment called MB-CART19.1 for people with severe systemic lupus erythematosus (SLE) that hasn't improved with standard therapies. About 29 adults will receive this cell therapy to see if it can safely put their lupus into remission. The goal is to contro…

This study tests a new treatment called MB-CART2019.1 in children and teens (ages 6 months to under 18) with B-cell cancers that have come back or not responded to other treatments. The therapy uses the patient's own immune cells, modified to fight cancer. The goal is to see if i…

This study follows about 40 people who received a Miltenyi CAR T cell therapy at least one year ago. Researchers will track side effects, overall health, and any return of cancer over the long term. The goal is to better understand the lasting safety and effects of this treatment…